Clinical Trial Detail

NCT ID NCT02657369
Title A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Eisai Inc.
Indications

thyroid gland cancer

Therapies

Lenvatinib

Age Groups:

No variant requirements are available.